Abstract
Non-metastasized, non-resectable hepatocellular carcinoma (HCC) in patients with Barcelona clinic liver cancer (BCLC) stages B and, in part, C (≈25%) can be treated by systemic immunotherapy or selective internal radiation therapy (SIRT). Therapies vary in terms of required infrastructure, medical specialization(s), facilities, preparation, conduct, and cost. Our objective was to undertake a cost-effectiveness analysis (CEA) and budget impact analysis (BIA) of SIRT – here: with 90Y-labelled glass microspheres (TheraSphere®) compared to immunotherapy with atezolizumab plus bevacizumab (A+B) – from the perspective of the German statutory health insurance (SHI).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
